Tag: market-access
-
MedTech Forum 2026 – Stockholm
When Competitiveness Became the Main Signal The MedTech Forum 2026 produced an unusually clear signal. Across three days of sessions and professional exchanges in Stockholm, discussions repeatedly returned to a concern extending beyond regulation alone: whether Europe can maintain the industrial conditions required to convert medical innovation into sustainable scale. MDR and IVDR remained important,…
-
IVD Industry Monograph No. 3
Beyond Market Access – Foundations for Sustaining Europe’s IVD Leadership Europe’s diagnostics industry shows visible continuity but declining structural durability. IVD’s share of healthcare expenditure fell from 0.80% in 2009 to 0.60% in 2023. Real growth is weak. Capital duration is stressed. Regulatory and evidence obligations fall disproportionately on smaller suppliers. Five structural gaps—competitiveness, fixed-burden…
-
ESCMID Global 2026 Munich
When Diagnostics Became Infrastructure ESCMID Global 2026 offered a clear view of how diagnostics is changing within infectious-disease management. Across five days in Munich, clinicians, microbiologists, researchers, public-health specialists, and industry participants gathered around an extensive scientific programme covering antimicrobial resistance, antibiotics, vaccines, surveillance, emerging pathogens, infection prevention, clinical microbiology, and the broader management of…
-
IVD Industry Monograph No. 2
Earning Position: How Evidence Becomes Authority Diagnostics fail not analytically but through Evidence Escape: evidence does not automatically become clinical authority. Seven evidence domains govern adoption—analytical, clinical, regulatory, economic, operational. Strength in one domain cannot compensate for weakness elsewhere. The binding-constraint principle identifies the missing domain preventing adoption. Connected laboratories are evidence-generating assets, not merely…